CA
NZ
UK
AU
IND
US
Imunon, Inc. (NASDAQ:IMNN) has exchanged $1,200,000 of principal on a note held by Streeterville Capital, LLC for 120 shares of a new Series B Preferred Stock, according to a Form 8-K filed on September 29, 2026.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) reported in a Form 8-K that stockholders approved several proposals at its 2026 annual meeting on September 22, 2026, including an increase in authorized common stock from 12.5 million to 100 million shares and board authority to carry out a …
Liminatus Pharma, Inc. (NASDAQ:LIMN) disclosed in a Form 8-K filed on September 29, 2026 that Nasdaq notified it on September 24, 2026 that it has regained compliance with the exchange's minimum bid price requirement. Nasdaq told the company that the closing bid price of …
Genmab A/S (NASDAQ:GMAB) furnished a Form 6-K on September 29, 2026 whose sole purpose is to place its current Articles of Association on the public record. The document, dated September 24, 2026, is attached as Exhibit 3.1, and the cover report states that it …
Charming Medical Ltd (NASDAQ:MCTA) filed a Form 6-K on September 29, 2026 attaching a notice of an extraordinary general meeting, a proxy statement and a form of proxy card. The meeting is set for October 23, 2026, with a record date of September 25, …
Nano-X Imaging Ltd. (NASDAQ:NNOX) furnished a Form 6-K reporting that its shareholders approved the proposals put to them at the company's adjourned annual general meeting, held on September 29, 2026 at Ofer Tech Park, 94 Shlomo Shmeltzer Road, Petach Tikva, Israel. One proposal, Proposal …
OKYO Pharma Ltd (NASDAQ:OKYO) furnished a Form 6-K on September 29, 2026, attaching a press release that lays out its participation in three ophthalmic conferences over the following two weeks. The release describes the company as a clinical-stage biopharmaceutical company developing therapies for neuropathic …
● Tectonic's TX2100 was generally safe and well tolerated in a Phase 1a trial of 48 healthy volunteers.
● TELA Bio's lenders agreed not to test the minimumRevenuecovenant for the next two quarterly measurement dates.
● Unicycive resubmitted its NDA for oxylanthanum carbonate withManufacturingdata from a new third-party drug product vendor.
Please wait processing your request...